---
search:
  boost: 3
---

# Immunomodulators

This is a subcategory of Topical Agents.

## Decision Trees

- [Topical - Immunomodulators - Non-Preferred - Eucrisa, Opzelura, Vtama, Zoryve](https://forms.office.com/Pages/ResponsePage.aspx?id=nPhjxpvvj0G9PUHkbAzgaN9UYz8EqmlIs3_TYn4TbXBUNEpQN1lHWjMzRjdHUTc1UDRLVkpON0UxOCQlQCNjPTEkJUAjdD1n){ :target="_blank" rel="noopener"}

- [Topical - Immunomodulators](https://forms.office.com/Pages/ResponsePage.aspx?id=nPhjxpvvj0G9PUHkbAzgaN9UYz8EqmlIs3_TYn4TbXBURFNHMjA4ME1NOEc0QVVDUjMyWklIUTNQMCQlQCNjPTEkJUAjdD1n){ :target="_blank" rel="noopener"}

## Formulary

### Preferred

| Preferred                   | Generic Name | Quantity | Time (Days) |
|:----------------------------|:-------------|:--------:|:-----------:|
| Elidel <sup>AR BvG ST</sup> |              |          |             |
| Tacrolimus <sup>AR ST</sup> |              |          |             |

### Non-Preferred

| Non-Preferred              | Generic Name | Quantity | Time (Days) |
|:---------------------------|:-------------|:--------:|:-----------:|
| Eucrisa                    |              |          |             |
| Hyftor                     |              |          |             |
| Opzelura                   |              |          |             |
| <span title = "Brand Preferred: Elidel">Pimecrolimus</span> <sup>AR, Brand Preferred</sup> |              |          |             |
| Vtama                      |              |          |             |
| Zoryve                     |              |          |             |

## Authorizations

**Length of Authorizations**: 365 Days

**All Authorizations**: Must be prescribed in accordance with FDA approved labeling

## Criteria

### Step Therapy

Step Therapy Approval Criteria

- Must have had an inadequate clinical response of at least **30 days** with at least **two** topical corticosteroids

### Non-Preferred

Non-Preferred Criteria

- Must provide documentation of medical necessity beyond convenience for why the patient cannot be changed to a preferred drug (i.e., allergies, drug-drug interactions, contraindications, or intolerances) **OR**
    - For any nonsolid oral dosage formulation: must provide documentation of medical necessity for why patient cannot be changed to a solid oral dosage formulation
- Must have had an inadequate clinical response to at least **30 days** with at least **one preferred** drug
    - For non-preferred extended-release formulations: must provide documentation of an inadequate clinical response with its immediate release formulation (if available)
    - For non-preferred brand names that have preferred generics: must provide documentation of an inadequate clinical response or allergy to two or more generic labelers (if available)

### Subsequent Authorization

Subsequent Authorization Criteria

- Must provide documentation of patient's clinical response to treatment and ongoing safety monitoring

**AR** - Pimecrolimus and Tacrolimus: a PA is required for patients younger than 2 years old

## Links

[Criteria](https://medicaid.ohio.gov/static/PHM/drug-coverage/20230701+UPDL+Criteria+_v1_FINAL.approved.pdf#page=104){ :target="_blank" rel="noopener"}

[Preferred Drug List](https://medicaid.ohio.gov/static/PHM/drug-coverage/20230701_UPDL_FINAL_ODM.approved.v2.pdf#page=33){ :target="_blank" rel="noopener"}

[Quantity Limit List](https://pharmacy.medicaid.ohio.gov/sites/default/files/20230101_Ohio_Medicaid_Quantity_Document_APPROVED.pdf){ :target="_blank" rel="noopener"}
